Dental revenues for RTI Biologics dropped 4% for the first quarter of 2010 (end-March 31), while overall revenues fell by 2% compared to the same quarter last year, the company announced.
The company, which prepares human and bovine tissue for grafting, lost $54,000 on $37.8 million in revenues, down from $38,600 for the first quarter of 2009.
Dental revenues were $7 million for the quarter, a decrease of 4%. Half of the decline was due to a change in overall volume, and half to a change in product mix, said Tom Rose, the company's chief financial officer, in a conference call.
In the U.S., dental revenues increased 2%, but the boost was more than offset by declines overseas.
Copyright © 2010 DrBicuspid.com
